List of Excipients in Branded Drug CORTENEMA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
ANI Pharmaceuticals Inc	CORTENEMA	hydrocortisone	62559-111	CARBOMER HOMOPOLYMER TYPE B
ANI Pharmaceuticals Inc	CORTENEMA	hydrocortisone	62559-111	METHYLPARABEN
ANI Pharmaceuticals Inc	CORTENEMA	hydrocortisone	62559-111	POLYSORBATE 80

CORTENEMA Excipient Strategy and Commercial Opportunities: Formulation, Regulatory, Patent, and Generic Market Analysis

Last updated: August 12, 2026

CORTENEMA is a legacy hydrocortisone retention enema containing 100 mg hydrocortisone in a 60 mL unit dose. Its commercial value depends less on active-ingredient exclusivity and more on formulation performance, patient usability, manufacturing reliability, supply continuity, and differentiated delivery systems. The product has no apparent modern composition-of-matter exclusivity, and its principal commercial opportunities are improved excipient systems, preservative reduction, lower-volume delivery, pediatric adaptation, and device-enabled lifecycle management.

What is CORTENEMA and how is it administered?

CORTENEMA is a rectally administered hydrocortisone product indicated for inflammatory conditions affecting the distal colon and rectum, including ulcerative proctitis and related inflammatory bowel conditions. The labeled presentation is a 100 mg dose in a 60 mL retention enema.

Attribute	CORTENEMA profile
Active ingredient	Hydrocortisone
Strength	100 mg per 60 mL
Dosage form	Rectal retention enema
Route	Rectal
Therapeutic area	Gastroenterology; inflammatory rectal disease
Primary use	Local corticosteroid treatment
FDA pathway	Legacy prescription product; regulatory status tied to its approved application and current labeling
Commercial format	Single-use rectal enema
Cold-chain requirement	No public indication of a cold-chain requirement
Biosimilar exposure	None; CORTENEMA is a small-molecule drug
Primary competitive threat	Generic hydrocortisone rectal products and alternative rectal corticosteroid formulations

The product is designed to retain the drug locally in the rectum and distal colon. Its commercial performance therefore depends on suspension uniformity, applicator function, dose delivery, spread, retention, microbiological quality, and patient tolerance.

What excipients are used in CORTENEMA?

CORTENEMA uses a water-based rectal vehicle containing hydrocortisone and a combination of surfactant, preservative, fatty alcohol, and aqueous-phase components. Public labeling identifies excipients including polysorbate 80, cetyl alcohol, methylparaben, propylparaben, and purified water. The exact current inactive-ingredient presentation should be controlled against the latest FDA labeling and product package insert before a formulation or regulatory filing is prepared. (ANI Pharmaceuticals, n.d.; U.S. Food and Drug Administration, n.d.-a)

What is the function of each major excipient?

Excipient category	Likely formulation role	Commercial significance
Polysorbate 80	Wetting, dispersion, and suspension support for hydrocortisone	Controls dose uniformity and redispersibility
Cetyl alcohol	Emulsion or suspension structure, viscosity modification, and vehicle consistency	Affects spread, retention, and sensory properties
Methylparaben	Antimicrobial preservation	May create tolerability and preservative-free reformulation opportunities
Propylparaben	Preservative support, particularly against fungi and yeasts	Requires control of concentration, solubility, and compatibility
Purified water	Continuous vehicle phase	Drives microbial control, viscosity, and stability
Hydrocortisone	Active corticosteroid	Poor aqueous solubility makes dispersion control important

Hydrocortisone is not highly water-soluble. The excipient system must keep the active evenly distributed throughout the product’s usable life and provide consistent dosing after shaking or other label-directed preparation. A formulation that separates rapidly or produces variable sediment can create dose-uniformity and patient-use risks.

How does the CORTENEMA excipient system affect product performance?

The central technical challenge is balancing physical stability with rectal tolerability.

A higher-viscosity vehicle may improve retention and reduce leakage, but excessive viscosity can impair administration through the applicator. A stronger surfactant system may improve wetting but can increase irritation or interact with packaging components. Fatty alcohols can influence texture and spread, while parabens support microbiological control but may be commercially disadvantageous in patients seeking preservative-free products.

Key quality attributes include:

1. Hydrocortisone assay and content uniformity.
2. Particle-size distribution.
3. Redispersibility after storage.
4. Sedimentation rate.
5. Viscosity and syringe or applicator force.
6. Microbial limits and preservative effectiveness.
7. pH and osmolality.
8. Extractables and leachables.
9. Container-closure integrity.
10. Delivered dose from the full applicator.

For a rectal suspension, dissolution testing alone does not adequately describe performance. A development program should connect in vitro dispersion and delivery data to clinically relevant administration behavior, including the amount delivered, retained, and recovered after use.

What excipient strategies could improve CORTENEMA?

Preservative-free reformulation

A preservative-free, single-dose presentation is the most direct excipient opportunity. Removing methylparaben and propylparaben could improve positioning for patients with local sensitivity concerns and simplify the product’s tolerability message.

The tradeoff is microbiological risk. A preservative-free product would require robust unit-dose packaging, validated aseptic or controlled manufacturing, strong container-closure integrity, and a product-specific in-use strategy. A preservative-free formulation in a multi-use container would be difficult to justify commercially and regulatorily.

Lower-irritancy surfactant system

Polysorbate 80 is widely used, but a reformulator could evaluate alternative wetting agents or lower surfactant concentrations. The objective would be to maintain hydrocortisone dispersion while reducing the total excipient burden.

Potential candidates include nonionic surfactants, phospholipid-based dispersants, or polymer-assisted wetting systems. Each candidate would require assessment of:

• Hydrocortisone particle wetting.
• Suspension settling.
• Redispersibility.
• Local tissue tolerance.
• Oxidative stability.
• Compatibility with the applicator and container.
• Preservative effectiveness.

A new surfactant system could support a 505(b)(2) strategy if it produces a clinically meaningful change in administration, tolerability, retention, or dose delivery. A purely cosmetic excipient substitution would have weaker differentiation value.

Bioadhesive polymer system

A low-concentration mucoadhesive polymer could increase residence time and reduce leakage. Possible polymer classes include cellulose derivatives, polycarbophil-type materials, carbomers, and selected natural polymers.

This approach has technical limits. A polymer that improves retention can also increase administration force, create clumping, interfere with dose uniformity, or produce an undesirable rectal sensation. The product must remain deliverable through the applicator and evenly redispersible after storage.

A successful bioadhesive system could support claims related to residence time or reduced leakage, but those claims would require clinical substantiation.

Lower-volume formulation

A 30 mL or other lower-volume presentation could improve patient acceptance, especially for patients who find a 60 mL enema difficult to retain. Lower volume creates a formulation challenge because the same 100 mg dose must be delivered in a more concentrated suspension.

Commercial benefits could include:

• Greater patient convenience.
• Better retention.
• Lower packaging and shipping costs.
• Improved suitability for outpatient and travel use.
• Potential differentiation from conventional 60 mL products.

The principal risks are increased viscosity, sedimentation, applicator force, and local concentration. A lower-volume product would likely require a new delivery-performance package and possibly a clinical bridge.

Osmolality and pH optimization

Rectal tolerability can be affected by pH, ionic strength, and osmolality. An optimized buffer and tonicity system could reduce discomfort and improve retention. The formulation should avoid unnecessary buffering because excessive buffer capacity can complicate local tolerability and manufacturing control.

The commercial value of pH or osmolality optimization is strongest when linked to measurable patient outcomes, such as reduced burning, improved retention, or improved adherence.

What formulations are protected by CORTENEMA patents?

CORTENEMA’s core formulation is a long-established hydrocortisone enema composition. Publicly available FDA and product information does not identify a current patent estate that creates a meaningful modern barrier around the active ingredient, the basic 100 mg/60 mL rectal presentation, or the legacy excipient combination. The product’s original exclusivity period expired decades ago.

IP category	CORTENEMA position	Commercial implication
Hydrocortisone composition of matter	Expired	No active molecule-level barrier
Basic hydrocortisone enema formulation	Legacy technology	Limited protection against conventional generic products
Polysorbate/paraben aqueous vehicle	Likely difficult to protect broadly today	Weak standalone differentiation
Applicator or container design	Potentially protectable if novel	Device claims may support lifecycle management
Preservative-free composition	Potentially protectable if technically distinctive	Requires meaningful formulation differences
Lower-volume suspension	Potentially protectable	Stronger if linked to stability and dose-delivery advantages
Bioadhesive rectal formulation	Potentially protectable	May support new-drug or 505(b)(2) positioning
Manufacturing process	Potentially protectable	Can create supply and scale barriers even without broad market exclusivity
Method of use	Potentially limited	Narrow disease, dosing, or patient-subgroup claims may be available

Patent protection for a reformulated CORTENEMA product would need to focus on measurable technical differences. Broad claims covering hydrocortisone in a rectal vehicle would face substantial prior-art and obviousness pressure.

When does CORTENEMA lose exclusivity?

CORTENEMA’s original small-molecule exclusivity has already expired. Its commercial protection is therefore based on product availability, manufacturing authorization, regulatory file ownership, brand recognition, and any later-issued patents or exclusivities associated with a specific reformulation.

Exclusivity type	Current assessment
New chemical entity exclusivity	Expired
Original product patent	Expired or no longer commercially relevant
Current formulation patent	No material public barrier identified
Orphan-drug exclusivity	Not identified
Pediatric exclusivity	Not identified
Biosimilar exclusivity	Not applicable
Generic entry	Legally possible subject to FDA approval and any applicable listed patent certifications

The Orange Book must be reviewed for the current marketed application, active ingredient, dosage form, and any listed patents. Legacy products can have complex approval histories, and brand ownership, NDA ownership, and manufacturing responsibility may change over time. (U.S. Food and Drug Administration, n.d.-b)

What is the Orange Book status of CORTENEMA?

The Orange Book is the controlling public source for approved drug products and listed patents. CORTENEMA should be assessed under its current FDA application and marketing status rather than by relying solely on historical brand references.

For a competitor, the relevant questions are:

• Whether the product has an active FDA-approved application.
• Whether CORTENEMA or its authorized generic equivalent is currently listed.
• Whether any patents are listed for the product.
• Whether the listed product is therapeutically equivalent to proposed generic products.
• Whether the reference product has an active exclusivity code.
• Whether any patent listing is subject to a Paragraph IV challenge.

No widely reported contemporary Paragraph IV campaign or major patent litigation appears to define the CORTENEMA market. The principal entry risk is conventional abbreviated new drug application competition rather than a high-value patent dispute.

Which companies are challenging CORTENEMA?

Publicly reported litigation and Paragraph IV activity involving CORTENEMA are limited compared with major branded drugs. The likely competitive set consists of generic manufacturers capable of producing hydrocortisone rectal dosage forms, contract manufacturers with suspension and liquid-dose capabilities, and companies developing alternative rectal corticosteroid delivery systems.

The market should be divided into four competitor groups:

Competitor group	Product strategy	Risk to CORTENEMA
Conventional hydrocortisone enema manufacturers	Match 100 mg/60 mL dosage form	High price and formulary pressure
Hydrocortisone foam manufacturers	Improve convenience and retention	Moderate substitution risk
Mesalamine rectal products	Alternative anti-inflammatory treatment	Indirect therapeutic competition
Compounded preparations	Local pharmacy supply and customized volumes	Fragmented price competition

CORTENEMA is a small-molecule product, so biosimilar competition is not relevant. Generic competition is the central regulatory and commercial issue.

What FDA regulatory pathways could support a CORTENEMA reformulation?

A conventional equivalent hydrocortisone enema would generally be pursued through an ANDA, assuming the reference-product and equivalence requirements are met. A materially different formulation or delivery system may require a 505(b)(2) application.

ANDA opportunity

An ANDA strategy is appropriate for a product that matches the reference product in dosage form, strength, route, and relevant performance characteristics. The commercial advantages are lower development cost and a more direct regulatory pathway.

The disadvantages are limited differentiation, rapid price erosion, and possible competition from multiple generic applicants.

505(b)(2) opportunity

A 505(b)(2) strategy may be more suitable for:

• Preservative-free delivery.
• Lower-volume administration.
• New applicator technology.
• Extended rectal residence.
• A novel mucoadhesive system.
• A different concentration or dosing schedule.
• A clinically supported tolerability improvement.
• A new patient population or disease use.

A 505(b)(2) product may obtain regulatory exclusivity for the approved innovation, but exclusivity does not automatically block all generic hydrocortisone products. The commercial value depends on whether the innovation is important enough to support premium pricing and whether the claims are difficult to design around.

What method-of-use patents could protect CORTENEMA?

Method-of-use protection is more plausible for a differentiated formulation than for the legacy product. Potential claim areas include:

• Treatment of ulcerative proctitis with a lower-volume hydrocortisone dose.
• Treatment in patients unable to tolerate conventional enemas.
• Use in a defined disease-severity subgroup.
• Use with a specific retention or dosing protocol.
• Combination use with oral or rectal anti-inflammatory therapy.
• Use after surgery or radiation injury, if supported by clinical data.

Method-of-use claims can be commercially weak when physicians routinely use the product for the claimed indication or when generic labeling can omit the patented use. A formulation patent covering the product itself is usually more valuable than a narrow use patent.

How strong is the CORTENEMA patent estate?

The legacy CORTENEMA patent estate is weak as a barrier to generic entry because the core active ingredient and basic dosage form are old. A new patent portfolio could be stronger if it covers several independent technical features.

A commercially useful lifecycle portfolio could include:

1. Composition claims covering a defined excipient range.
2. Particle-size and suspension-stability claims.
3. Preservative-free unit-dose packaging.
4. Low-volume, high-concentration formulations.
5. Mucoadhesive or extended-retention systems.
6. Applicator geometry and dose-delivery claims.
7. Manufacturing-process claims.
8. Stability claims tied to a defined shelf life.
9. Method-of-use claims for selected patient groups.

The strongest claims would connect composition, device, and performance. A patent covering only the presence of hydrocortisone, water, and a conventional surfactant would face a high invalidity and design-around risk.

What manufacturing and IP barriers affect CORTENEMA?

Manufacturing barriers are more meaningful than molecule-level IP barriers.

A manufacturer must control:

• Hydrocortisone particle size and morphology.
• Powder wetting and dispersion.
• Suspension homogeneity during filling.
• Filling accuracy for 60 mL units.
• Applicator compatibility.
• Microbial control.
• Preservative effectiveness, where applicable.
• Container-closure integrity.
• Long-term and accelerated stability.
• Shipping stress and temperature exposure.

Rectal suspensions can be operationally more difficult than simple solutions. The product must remain uniform during filling and storage, while the manufacturing process must avoid excessive aeration, sedimentation, and batch-to-batch viscosity variation.

These issues can create a practical barrier for smaller entrants even when legal exclusivity is absent. A reliable contract manufacturing organization with liquid and semisolid capabilities may therefore have strategic value.

What commercial opportunities exist for CORTENEMA?

Premium reformulation

A preservative-free, lower-volume, easy-to-administer product could command a premium over conventional generic enemas if it demonstrates improved tolerability or adherence.

Specialty gastroenterology positioning

The product could be positioned through gastroenterology and colorectal practices, particularly where local therapy is preferred for distal disease and systemic corticosteroid exposure should be limited.

Hospital and institutional supply

Hospitals, outpatient centers, and integrated delivery networks may value reliable supply, standardized packaging, and predictable administration. The opportunity is more likely to be volume-based than premium-priced.

Pediatric or adolescent presentation

A smaller volume, softer applicator, or age-appropriate delivery system could address usability barriers. Pediatric claims would require suitable safety, dosing, and device evidence.

Combination-treatment positioning

CORTENEMA could be developed as part of a treatment regimen with oral or rectal mesalamine. Combination claims require clinical support and would face competition from established inflammatory bowel disease products.

Private-label and licensing

A company with a validated formulation and manufacturing process could license the product to specialty-pharmaceutical firms, generic suppliers, or regional distributors. The most valuable licensing asset would be a differentiated formulation with regulatory precedent, not an undifferentiated hydrocortisone suspension.

What revenue exposure does CORTENEMA represent?

CORTENEMA is a niche prescription product. Public company filings generally do not isolate CORTENEMA revenue from broader product portfolios, so product-specific revenue exposure cannot be quantified from standard public reporting.

Its commercial value is best assessed through:

• Annual prescription volume.
• Net price after rebates and discounts.
• Share of rectal corticosteroid prescriptions.
• Generic substitution rate.
• Supply reliability.
• Payer coverage.
• Patient persistence and refill behavior.
• Cost of goods for the liquid suspension and applicator.

The largest revenue risk is rapid price erosion from generic entry. The largest upside is a differentiated reformulation that converts a legacy product into a convenience- or tolerability-driven specialty product.

How does CORTENEMA compare with alternative rectal corticosteroid products?

Product type	Main advantage	Main limitation	Competitive position
Hydrocortisone enema	Broad distal-colon coverage and established use	Larger administration volume; retention burden	Direct legacy competitor
Hydrocortisone foam	Lower apparent volume and easier administration	May provide different anatomic coverage	Strong convenience substitute
Hydrocortisone suppository	Simple administration	More limited proximal distribution	Alternative for rectal disease
Mesalamine enema	Disease-directed anti-inflammatory therapy	Higher cost and different mechanism	Important therapeutic competitor
Compounded hydrocortisone liquid	Flexible concentration and volume	Variable quality and limited standardization	Price and customization competitor

CORTENEMA’s strongest strategic weakness is the 60 mL administration burden. Its strongest advantages are familiarity, local corticosteroid activity, and the possibility of manufacturing at scale without cold-chain requirements.

What generic launch scenarios exist for CORTENEMA?

Scenario 1: Conventional generic entry

A generic manufacturer matches the established strength and dosage form. Prices decline, formulary substitution increases, and the brand competes mainly through supply reliability.

Scenario 2: Multiple-source commodity market

Several manufacturers enter, producing deep price erosion. Distribution and manufacturing efficiency become more important than brand recognition.

Scenario 3: Differentiated 505(b)(2) reformulation

A company introduces a preservative-free, lower-volume, or bioadhesive product. The product may preserve premium pricing but must prove a meaningful patient or clinician benefit.

Scenario 4: Delivery-system substitution

Hydrocortisone foam, suppository, or another rectal delivery system captures prescriptions from patients unwilling or unable to use a 60 mL enema.

Scenario 5: Supply-constrained niche

Limited manufacturing capacity or intermittent shortages allow a reliable supplier to maintain share and pricing despite weak patent protection.

What licensing deals or settlements affect CORTENEMA?

No major publicly reported licensing transaction or patent settlement appears to define the CORTENEMA market. Licensing value would likely arise from:

• A novel rectal delivery device.
• A preservative-free suspension platform.
• A bioadhesive excipient system.
• A lower-volume formulation.
• Manufacturing rights in specific geographic markets.
• An authorized-generic arrangement.

A settlement would be commercially material only if it included a delayed generic-entry date, an authorized generic provision, or restrictions related to a newly patented reformulation. No such widely reported settlement is associated with the legacy CORTENEMA product.

What geographic markets offer opportunities?

The United States offers the clearest regulatory pathway through an ANDA or 505(b)(2) strategy, but it is also the most exposed to generic price competition.

Other opportunities may exist in markets where:

• Rectal corticosteroids remain widely prescribed.
• Local manufacturing is limited.
• Import substitution is encouraged.
• A lower-volume or preservative-free product has clinical value.
• Gastroenterology access is expanding.
• Regulatory reliance pathways reduce development time.

Geographic expansion requires country-specific review of hydrocortisone status, prescription classification, excipient acceptability, device requirements, and local bioequivalence expectations. European and other international markets may classify the product under different regulatory frameworks from the U.S. NDA system.

Key Takeaways

• CORTENEMA is a 100 mg/60 mL hydrocortisone retention enema for local rectal and distal-colon treatment.
• Its core molecule and legacy dosage form have no meaningful modern exclusivity barrier.
• The principal excipient strategy is to improve suspension stability, retention, tolerability, and dose delivery.
• Preservative-free, lower-volume, and bioadhesive formulations offer the strongest lifecycle opportunities.
• Conventional generic entry is legally and technically feasible, with price erosion as the primary risk.
• Biosimilar competition is irrelevant because hydrocortisone is a small molecule.
• A differentiated reformulation would likely require a 505(b)(2) strategy rather than a conventional ANDA.
• Device and manufacturing patents may provide stronger commercial protection than broad excipient claims.
• Product-specific revenue is not separately disclosed in standard public filings.
• The most attractive commercial asset is a validated, patient-friendly formulation with reliable manufacturing and a defensible regulatory pathway.

FAQs

Can CORTENEMA be reformulated without changing the active ingredient?

Yes. The active ingredient can remain hydrocortisone while the vehicle, preservative system, concentration, volume, applicator, or retention properties are changed. The regulatory pathway depends on the extent and clinical significance of the changes.

Is a preservative-free CORTENEMA commercially attractive?

Yes, if the product uses single-dose packaging and demonstrates acceptable microbiological quality, stability, and local tolerability. Preservative removal alone may not justify premium pricing without a clear patient benefit.

Could a lower-volume hydrocortisone enema receive separate patent protection?

Yes, if the lower-volume product has a novel and nonobvious composition, concentration, stability profile, delivery system, or performance advantage. A simple volume reduction without technical differentiation would be more vulnerable to invalidity and design-around arguments.

Is CORTENEMA suitable for an authorized-generic strategy?

Yes. An authorized generic could address institutional and payer demand while preserving manufacturing scale. The strategy would be most useful where brand pricing is exposed to substitution but supply reliability remains valuable.

Which excipient is most important to CORTENEMA product performance?

The suspension and wetting system, including polysorbate 80 and the vehicle-structuring components, is central to dose uniformity, redispersibility, retention, and administration. Preservatives are important for microbiological control but are also the clearest target for a tolerability-focused reformulation.

References

ANI Pharmaceuticals. (n.d.). Cortenema hydrocortisone retention enema prescribing information. https://www.anipharmaceuticals.com/

U.S. Food and Drug Administration. (n.d.-a). CORTENEMA- hydrocortisone enema. DailyMed. https://dailymed.nlm.nih.gov/

U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

U.S. Food and Drug Administration. (2019). ANDAs for certain highly purified synthetic peptides. FDA guidance and abbreviated new drug application materials. https://www.fda.gov/

U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP.